Novel chewable tablet-in-tablet dosage form of Orlistat and Venlafaxine hydrochloride: development and evaluation.
Loading...
Date
2015-03
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Obesity is a chronic pathological condition characterized by an increased body fat accumulation to the extent that
it may have an adverse effect on the health. Depression is the most common co-morbidity of obesity, which may
cause the Binge Eating Disorder (BED), leading to morbid obesity. In the present project a dispersible 60mg
Orlistat (ORST) and β-cyclodextrin (β-CD), (1:2M) complexed core tablet is press coated with the taste masked
75mg Venlafaxine Hcl. (VLFXN) microparticles, prepared with Eudragit EPO (1:3), by emulsification solvent
evaporation method, to obtain the chewable tablet-in-tablet dosage form. A Reverse phase (RP)-HPLC method
was developed for the simultaneous estimation of ORST and VLFXN in the formulation. The optimized
formulation was palatable and there was no drug excipients interaction which was confirmed by IR Spectrum.
Press coated, tablet-in-tablets were evaluated for physicochemical properties. All the values obtained were within
the standard limits. And in the in-vitro dissolution study the release of both drugs, ORST and VLFXN at the end
of 15mins was found to be 86% and 92% respectively. Hence, the developed chewable tablet-in-tablet
formulation of ORST and VLFXN can be a viable drug delivery system for treating patients with obesity and
BED.
Description
Keywords
Orlista, Venlafaxine, Anti-obesity, Binge eating obesity, Chewable, Tablet-in-Tablet
Citation
Mannan Abdul, Rao K Purushotham. Novel chewable tablet-in-tablet dosage form of Orlistat and Venlafaxine hydrochloride: development and evaluation. Journal of Applied Pharmaceutical Science. 2015 Mar; 5(3): 91-97.